GlassScriptPhysician profile
Natalie Kerber
NPI 1184075160
$11,961.68
in general payments reported to CMS, 2019-2025
48 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,158 · 2022: $2,062 · 2023: $1,950 · 2024: $2,848 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,652 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,651.74 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,021.47 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $2,013.14 | 2021-2025 | |
| Lilly USA, LLC | $1,114.02 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $722.11 | 2022-2025 | |
| Pfizer INC. | $566.89 | 2023-2025 | |
| Ironwood Pharmaceuticals, INC | $512.26 | 2021-2024 | Linzess |
| Astellas Pharma US INC | $440.11 | 2021-2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $406.23 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $344.80 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.19 | 2021-2023 | Xifaxan |
| Daiichi Sankyo INC. | $277.27 | 2021-2023 | Injectafer |
| Glaxosmithkline, LLC. | $266.47 | 2021-2024 | Bexsero, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.21 | 2021-2025 | Jardiance |
| Amgen INC. | $219.28 | 2021-2025 | Repatha, Otezla, Otezla |
| Ardelyx, INC. | $188.87 | 2023-2025 | Ibsrela |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $173.54 | 2024-2025 | Zenpep |
| Hologic Sales and Service, LLC | $151.31 | 2023-2025 | Aptima |
| Takeda Pharmaceuticals U.S.A., INC. | $130.75 | 2021 | |
| Axsome Therapeutics, INC. | $124.95 | 2024-2025 | Symbravo, Auvelity |
| Lundbeck LLC | $115.13 | 2024-2025 | Rexulti, Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.37 | 2025 | Caplyta |
| Exeltis, USA INC. | $113.10 | 2022-2025 | Slynd |
| Exact Sciences Corporation | $108.85 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $105.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $99.18 | 2021-2025 | |
| Sanofi Pasteur INC. | $95.64 | 2021-2023 | |
| Corcept Therapeutics | $88.21 | 2023 | Korlym |
| Nestle Healthcare Nutrition INC. | $87.39 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $87.19 | 2021-2022 | |
| Dexcom, INC. | $86.58 | 2021-2025 | Dexcom G6 Transmitter |
| Cranial Technologies, INC | $78.71 | 2024-2025 | Doc Band |
| Biohaven Pharmaceutical Holding Company LTD. | $75.05 | 2022 | |
| Agile Therapeutics, INC. | $68.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $54.02 | 2024-2025 | Eliquis, Camzyos |
| Otsuka America Pharmaceutical, INC. | $53.77 | 2022-2025 | Rexulti |
| Alkermes, INC. | $52.89 | 2022 | |
| Xeris Pharmaceuticals, INC. | $48.70 | 2024-2025 | Gvoke Hypopen |
| Ibsa Pharma INC. | $26.90 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.27 | 2021 | |
| Vanda Pharmaceuticals INC. | $23.85 | 2024 | Fanapt |
| Pulmonx Corporation | $22.66 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Scynexis, INC. | $20.42 | 2022 | |
| Avion Pharmaceuticals | $17.75 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.56 | 2023 | Livalo |
| Qol Medical, LLC | $16.32 | 2021 | |
| Eisai INC. | $15.90 | 2021 | |
| Viiv Healthcare Company | $15.21 | 2024 | Apretude |
| Phadia US INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Kerber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.